Evidence map›Paper›PMID 35194965›Full record

ArticleJournal of cachexia, sarcopenia and muscle2022

Muscle cells of sporadic amyotrophic lateral sclerosis patients secrete neurotoxic vesicles.

Laura Le Gall, William J Duddy, Cecile Martinat, Virginie Mariot, Owen Connolly, Vanessa Milla, Ekene Anakor, Zamalou G Ouandaogo, Stephanie Millecamps, Jeanne Lainé and 29 more

Open access · goldAbstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review of the Pathology of Muscle in Amyotrophic Lateral Sclerosis.International journal of molecular sciences · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors at 11 institutions in 4 countries.

Laura Le GallNorthern Ireland Center for Stratified Medicine, Biomedical Sciences Research Institute, Londonderry, UK.
William J DuddyNorthern Ireland Center for Stratified Medicine, Biomedical Sciences Research Institute, Londonderry, UK.
Cecile MartinatI-Stem, INSERM/UEVE UMR 861, I-STEM, AFM, Paris, France.
Virginie MariotNIHR Biomedical Research Centre, University College London, Great Ormond Street Institute of Child Health and Great Ormond Street Hospital NHS Trust, London, UK.
Owen ConnollyNorthern Ireland Center for Stratified Medicine, Biomedical Sciences Research Institute, Londonderry, UK.
Vanessa MillaNorthern Ireland Center for Stratified Medicine, Biomedical Sciences Research Institute, Londonderry, UK.
Ekene AnakorNorthern Ireland Center for Stratified Medicine, Biomedical Sciences Research Institute, Londonderry, UK.
Zamalou G OuandaogoSorbonne Université, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, Centre de Recherche en Myologie, Paris, France.
Stephanie MillecampsInserm U1127, CNRS UMR7225, Sorbonne Universités, UPMC Univ, Paris, France.
Jeanne LainéSorbonne Université, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, Centre de Recherche en Myologie, Paris, France.
Udaya Geetha VijayakumarNorthern Ireland Center for Stratified Medicine, Biomedical Sciences Research Institute, Londonderry, UK.
Susan KnoblachGenetic Medicine, Children's National Medical Center, George Washington University, Washington, DC, USA.
Cedric RaoulThe Neuroscience Institute of Montpellier, Inserm UMR1051, Univ Montpellier, Saint Eloi Hospital, Montpellier, France.
Olivier LucasThe Neuroscience Institute of Montpellier, Inserm UMR1051, Univ Montpellier, Saint Eloi Hospital, Montpellier, France.
Jean Philippe LoefflerMécanismes Centraux et Périphériques de la Neurodégénérescence, Université de Strasbourg, INSERM UMR_S 1118, Strasbourg, France.
Peter BedeComputational Neuroimaging Group, Academic Unit of Neurology, Trinity College Dublin, Dublin, Ireland.
Anthony BehinAPHP, Centre de Référence des Maladies Neuromusculaires Nord/Est/Ile de France, Institut de Myologie, Hôpital Pitié-Salpêtrière, Paris, France.
Helene BlascoLaboratoire de Biochimie et Biologie Moléculaire, Hôpital Bretonneau, CHRU de Tours, Tours, France.
Gaelle BruneteauSorbonne Université, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, Centre de Recherche en Myologie, Paris, France.
Maria Del Mar AmadorAPHP, Département de Neurologie, Hôpital Pitié-Salpêtrière, Centre référent SLA, Paris, France.
David DevosINSERM U1171, Pharmacologie Médicale & Neurologie Université, Faculté de Médecine, CHU de Lille, Lille, France.
Alexandre HenriquesMécanismes Centraux et Périphériques de la Neurodégénérescence, Université de Strasbourg, INSERM UMR_S 1118, Strasbourg, France.
Adele HestersAPHP, Département de Neurologie, Hôpital Pitié-Salpêtrière, Centre référent SLA, Paris, France.
Lucette LacomblezCNRS, INSERM, Laboratoire d'Imagerie Biomédicale, Sorbonne Université, Paris, France.
Pascal LaforetDépartement de Neurologie, Centre de Référence Maladies Neuromusculaires Paris-Est, Hôpital Raymond-Poincaré, Garches, France.
Timothee LangletAPHP, Département de Neurologie, Hôpital Pitié-Salpêtrière, Centre référent SLA, Paris, France.
Pascal LeblancLaboratory of Molecular Biology of the Cell, Ecole Normale Supérieure de Lyon, Lyon, France.
Nadine Le ForestierAPHP, Département de Neurologie, Hôpital Pitié-Salpêtrière, Centre référent SLA, Paris, France.
Thierry MaisonobeAPHP, Département de Neurologie, Hôpital Pitié-Salpêtrière, Centre référent SLA, Paris, France.
Vincent MeiningerHôpital des Peupliers, Ramsay Générale de Santé, Paris, France.
Laura RobelinMécanismes Centraux et Périphériques de la Neurodégénérescence, Université de Strasbourg, INSERM UMR_S 1118, Strasbourg, France.
Francois SalachasAPHP, Département de Neurologie, Hôpital Pitié-Salpêtrière, Centre référent SLA, Paris, France.
Tanya StojkovicAPHP, Centre de Référence des Maladies Neuromusculaires Nord/Est/Ile de France, Institut de Myologie, Hôpital Pitié-Salpêtrière, Paris, France.
Giorgia QuerinCNRS, INSERM, Laboratoire d'Imagerie Biomédicale, Sorbonne Université, Paris, France.
Julie DumonceauxNIHR Biomedical Research Centre, University College London, Great Ormond Street Institute of Child Health and Great Ormond Street Hospital NHS Trust, London, UK.
Gillian Butler BrowneSorbonne Université, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, Centre de Recherche en Myologie, Paris, France.
Jose-Luis González De AguilarMécanismes Centraux et Périphériques de la Neurodégénérescence, Université de Strasbourg, INSERM UMR_S 1118, Strasbourg, France.
Stephanie DuguezNorthern Ireland Center for Stratified Medicine, Biomedical Sciences Research Institute, Londonderry, UK.ORCID 0000-0001-6510-5426
Pierre Francois PradatNorthern Ireland Center for Stratified Medicine, Biomedical Sciences Research Institute, Londonderry, UK.
Inserm · FRSorbonne Université · FRCentre National de la Recherche Scientifique · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Universitaire de Tours · FRChildren's National · USÉcole Normale Supérieure de Lyon · FRGénérale de Santé · FRGreat Ormond Street Hospital · GBHôpital Raymond-Poincaré · FRSt Thomas' Hospital · GB

Funding

ARsLAEuropean Community's Health Seventh Framework Programme 259867European Union Regional Development FundNorthern Ireland Public Health AgencyTarget-ALSUlster University
6 · The paper itself

Abstract

backgroundThe cause of the motor neuron (MN) death that drives terminal pathology in amyotrophic lateral sclerosis (ALS) remains unknown, and it is thought that the cellular environment of the MN may play a key role in MN survival. Several lines of evidence implicate vesicles in ALS, including that extracellular vesicles may carry toxic elements from astrocytes towards MNs, and that pathological proteins have been identified in circulating extracellular vesicles of sporadic ALS patients. Because MN degeneration at the neuromuscular junction is a feature of ALS, and muscle is a vesicle-secretory tissue, we hypothesized that muscle vesicles may be involved in ALS pathology.

methodsSporadic ALS patients were confirmed to be ALS according to El Escorial criteria and were genotyped to test for classic gene mutations associated with ALS, and physical function was assessed using the ALSFRS-R score. Muscle biopsies of either mildly affected deltoids of ALS patients (n = 27) or deltoids of aged-matched healthy subjects (n = 30) were used for extraction of muscle stem cells, to perform immunohistology, or for electron microscopy. Muscle stem cells were characterized by immunostaining, RT-qPCR, and transcriptomic analysis. Secreted muscle vesicles were characterized by proteomic analysis, Western blot, NanoSight, and electron microscopy. The effects of muscle vesicles isolated from the culture medium of ALS and healthy myotubes were tested on healthy human-derived iPSC MNs and on healthy human myotubes, with untreated cells used as controls.

resultsAn accumulation of multivesicular bodies was observed in muscle biopsies of sporadic ALS patients by immunostaining and electron microscopy. Study of muscle biopsies and biopsy-derived denervation-naïve differentiated muscle stem cells (myotubes) revealed a consistent disease signature in ALS myotubes, including intracellular accumulation of exosome-like vesicles and disruption of RNA-processing. Compared with vesicles from healthy control myotubes, when administered to healthy MNs the vesicles of ALS myotubes induced shortened, less branched neurites, cell death, and disrupted localization of RNA and RNA-processing proteins. The RNA-processing protein FUS and a majority of its binding partners were present in ALS muscle vesicles, and toxicity was dependent on the expression level of FUS in recipient cells. Toxicity to recipient MNs was abolished by anti-CD63 immuno-blocking of vesicle uptake.

conclusionsALS muscle vesicles are shown to be toxic to MNs, which establishes the skeletal muscle as a potential source of vesicle-mediated toxicity in ALS.

Indexed as

Amyotrophic Lateral SclerosisInduced Pluripotent Stem CellsAgedHumansMotor NeuronsMuscle CellsProteomicsCell-cell communicationMNDSecreted vesiclessporadic ALS

Identifiers

PMID35194965
PMCPMC8978001
OpenAlexW4213431709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.